Search
Close this search box.

John Milad named CEO of CRISPR play ERS Genomics

ARTICLE | Management Tracks

Plus: Senhwa hires Jason Huang as CMO, and updates from Egle and The Jackson Laboratory

By Gunjan Ohri, Data Content Analyst  

May 14, 2024 1:23 AM UTC

John Milad became CEO of ERS Genomics Ltd., a CRISPR licensing company. Milad was CEO of Quanta Dialysis Technologies Ltd. for over13 years, and then became a partner and co-head of healthcare ventures at Downing LLP. ERS Genomics provides access to the CRISPR/Cas9 CVC intellectual property held by Emmanuelle Charpentier.

DNA damage response therapies company  Senhwa Biosciences Inc. (TPEx:6492) hired Jason Huang as CMO, effective June 3. Huang was regional therapeutic area expert at Johnson & Johnson Innovative Medicine unit of Johnson & Johnson (NYSE:JNJ)…